| Sanofi-Aventis (Suisse) SA - Efluelda 0.7 ml, suspension injectable en seringue préremplie |
| 67704 | | 04 | | Efluelda 0.7 ml | | suspension injectable en seringue préremplie | | J07BB02 | | Influenza, gereinigtes Antigen | | 16.08.2024 | | |
|
| Composition |
| haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 60 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Thailand/8/2022 (H3N2)-like: reassortant virus SAN-022 derived from A/California/122/2022) 60 µg, haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: derived from B/Michigan/01/2021 (Victoria lineage)(wild type)) 60 µg, haemagglutininum influenzae B (Virus souche B/Phuket/3073/2013 (Yamagata lineage) (wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. |
| Packungsbestandteile |
| suspension injectable en seringue préremplie | | | | | | | | Principe actif | Concentr. |
|---|
| Haemagglutininum Influenzae a (H1N1) (Virus Souche A/victoria/4897/2022 (H1N1)-Like: Reassortant Virus Ivr-238 Derived from A/victoria/4897/2022) | 60µg / 0.7ml | | Haemagglutininum Influenzae a (H3N2) (Virus Souche A/thailand/8/2022 (H3N2)-Like: Reassortant Virus San-022 Derived from A/california/122/2022) | 60µg / 0.7ml | | Haemagglutininum Influenzae b (Virus Souche B/austria/1359417/2021-Like: Derived from B/michigan/01/2021 (Victoria Lineage)(wild Type)) | 60µg / 0.7ml |
| | BAG: Principe actif | Concentr. |
|---|
| Influenza-haemagglutinine | 240 mcg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Disodium Phosphate | | | Haemagglutininum Influenzae b (Virus Souche B/phuket/3073/2013 (Yamagata Lineage) (Wild Type)) | 60µg / 0.7ml | | Sodium Chlorure | | | Sodium Dihydrogenophosphate Anhydre | | | Octoxinolum-9 | |
| |
|
|
